Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction: Evidence Meets Practice, Part II.

Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction: Evidence Meets Practice, Part II.
J Cardiovasc Nurs. 2016 Nov/Dec;31(6):545-554
Authors: McIlvennan CK, Page RL
Abstract
Pharmacologic treatment for systolic heart failure, otherwise known as heart failure with reduced ejection fraction, has been established through clinical trials and is formulated into guidelines to standardize the diagnosis and treatment. Since the introduction of angiotensin-converting enzyme inhibitors and vasodilators in the 1980s, many guideline-recommended therapies have emerged over the past 20 years targeting specific neurohormones, aldosterone, and catecholamines to treat heart failure. Part 2 of this series will describe β-blockers, digoxin, and aldosterone antagonists in the context of the mechanism of action in heart failure, investigational trials that showed beneficial effects, and the practical applications for clinical use.
PMID: 27028591 [PubMed - in process]

Source: The Journal of Cardiovascular Nursing - October 20, 2016 Category: Nursing Authors: McIlvennan CK, Page RL Tags: J Cardiovasc Nurs Source Type: research